Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Depression in MS Patients

Evaluating prevalence of therapy

Publish date:: December 22, 2015

A large proportion of patients with MS and depression are now receiving treatment, a change from previous reports, according to a survey of 152 patients with MS. Researchers found:

• 65% of patients with major depression were taking antidepressants.

• With adjustment for successful treatment, the prevalence of treated depression rose to 85.7%.

• Of those receiving treatment for depression, 19% were receiving nonpharmacological treatment alone, 38% were taking antidepressant drugs only, and 44% were receiving pharmacological and nonpharmacological treatments.

• Demographic and clinical variables were not statistically significantly associated with antidepressant drug use in patients with MS and depression.

Citation: Raissi A, Bulloch AG, Fiest KM, McDonald K, Jetté N, Patten SB. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. Int J MS Care. 2015;17(6):292-300. doi: 10.7224/1537-2073.2014-084.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,